Selected Publications
- Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D'Argenio DZ, Hershberger PA. A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D3 is revealed using a novel LC-MS/MS assay. Steroids. 2012. Apr;77(5):477-83.
- Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Figg WD, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I Trial of the Combination of Flavopiridol and Imatinib Mesylate in Patients with Bcr-Abl+ Hematological Malignancies. Cancer Chemotherapy and Pharmacology. 2012 Feb 15 [Epub].
- Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani C, Gandara D, Allen D, Kiesel B, Beumer JH, Newman E, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders R, Parchment RE, Tomaszewski JE, Doroshow JH. A Phase I Study of Veliparib (ABT-888) in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research. 2012 Mar 15;18(6):1726-1734.
- Zhang Q, Kanterewicz B, Buch S, Parise RA, Beumer JH, Lin Y, Hershberger PA. CYP24 inhibition preserves 1,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cells. Molecular and Cellular Endocrinology. 2012 May 15;355(1):153-61.
- Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, Delacruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol. 2012 Apr;69(4):1089-97.
- Mulder KE, Egorin MJ, Sawyer MB. Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib. Invest New Drugs. 2011 Nov 25 [Epub].
- Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI, Rosen MP. Will imatinib compromise reproductive capacity? Oncologist. 2011;16(10):1422-7.
- Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47.




